STOCK TITAN

LivaNova Confirms Receipt of Letter from PrimeStone Capital

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

LivaNova PLC (NASDAQ:LIVN) has acknowledged a letter from PrimeStone Capital LLP, expressing openness to constructive dialogue aimed at enhancing shareholder value. The Company’s leadership has engaged in discussions with PrimeStone over the last few months, reaffirming its commitment to executing its strategic plan and improving patient outcomes through innovative medical technologies. An update on Company performance is scheduled for the third quarter earnings call on October 29, 2020.

Positive
  • Ongoing communication with PrimeStone suggests potential for strategic improvements.
  • Commitment to enhancing shareholder value is clearly stated by the Board of Directors.
  • The upcoming Q3 earnings call on October 29, 2020, could provide insights into performance and strategies.
Negative
  • None.

LONDON--()--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today confirmed receipt of a letter from PrimeStone Capital LLP (PrimeStone) to its Board of Directors and issued the following statement:

“LivaNova welcomes open communication and values constructive input toward the goal of enhancing value for all LivaNova shareholders. The Company’s Board of Directors and management will continue to take actions to achieve this objective. Members of the Company’s executive leadership team and the Board have held discussions with PrimeStone over the past several months.

LivaNova regularly evaluates the Company’s strategic plan and remains focused on execution, while upholding its mission to provide hope for patients through innovative medical technologies and to deliver life-changing improvements for the Head and Heart.”

LivaNova will provide an update on Company performance during its third quarter 2020 earnings call on Thursday, October 29.

About LivaNova

LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 4,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. LivaNova operates as two businesses: Cardiovascular and Neuromodulation, with operating headquarters in Mirandola (Italy) and Houston (U.S.), respectively.

For more information, please visit www.livanova.com.

Safe Harbor Statement

This news release contains “forward-looking statements” concerning our goals, beliefs, expectations, strategies, objectives, plans and underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding correspondence or meetings with shareholders. Actual results may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019, as supplemented by any risk factors contained in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. We undertake no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contacts

LivaNova PLC Investor Relations and Media Contacts

Melissa Farina, +1 (281) 228-7262
VP, Investor Relations
InvestorRelations@livanova.com

Deanna Wilke, +1 (281) 727-2764
VP, Corporate Communications
Corporate.Communications@livanova.com

FAQ

What recent communication has LivaNova had with PrimeStone Capital?

LivaNova confirmed receipt of a letter from PrimeStone Capital and expressed willingness to engage in open dialogue to enhance shareholder value.

When will LivaNova provide updates on its performance?

LivaNova will discuss its performance during the third quarter earnings call on October 29, 2020.

What is LivaNova's focus regarding its strategic plan?

LivaNova remains focused on executing its strategic plan while enhancing value for shareholders and delivering innovative medical technologies.

What is the significance of the letter from PrimeStone to LivaNova?

The letter from PrimeStone emphasizes the importance of constructive communication, which could lead to strategic advancements that benefit shareholders.

LivaNova PLC Ordinary Shares

NASDAQ:LIVN

LIVN Rankings

LIVN Latest News

LIVN Stock Data

2.90B
53.69M
0.33%
101.09%
3.64%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
LONDON